CPIX - Cumberland Pharmaceuticals Inc.
| Previous Close | 5.82 |
| Open | 5.88 |
| Bid | 0.00 x 1200 |
| Ask | 0.00 x 800 |
| Day's Range | 5.88 - 6.07 |
| 52 Week Range | 4.83 - 7.00 |
| Volume | 1,733 |
| Avg. Volume | 8,940 |
| Market Cap | 90.985M |
| Beta (3Y Monthly) | 0.09 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.45 |
| Earnings Date | May 6, 2019 - May 10, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.00 |
- Simply Wall St.•17 hours ago
The Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Is Up 31% And Shareholders Are Holding On
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shareholders have seen the share price descend 10% over the month. On the bright side the share price is up over the last half decade. In that time, it is up 31%, which...
- PR Newswire•25 days ago
Cumberland Pharmaceuticals Announces Strategic Review
NASHVILLE, Tenn., March 29, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX), a specialty pharmaceutical company, today announced that it has commenced a strategic review of its branded product portfolio, as well as its roster of international partners. The Company expects to communicate results from the review during its upcoming report on the first quarter of 2019. Following the Company's acquisition of Vibativ® in late 2018, its commercial portfolio now includes eight FDA-approved brands.
- GuruFocus.com•last month
Cumberland Pharmaceuticals Inc (CPIX) Files 10-K for the Fiscal Year Ended on December 31, 2018
Warning! GuruFocus has detected 3 Warning Signs with CPIX. For the last quarter Cumberland Pharmaceuticals Inc reported a revenue of $13.5 million, compared with the revenue of $11.65 million during the same period a year ago. For the last five years Cumberland Pharmaceuticals Inc had an average revenue growth rate of 4.4% a year.
- Simply Wall St.•2 months ago
Is Cumberland Pharmaceuticals Inc.’s (NASDAQ:CPIX) CEO Being Overpaid?
A. Kazimi has been the CEO of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) since 1999. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. ThenRead More...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CPIX earnings conference call or presentation 26-Feb-19 9:30pm GMT
Q4 2018 Cumberland Pharmaceuticals Inc Earnings Call
- PR Newswire•2 months ago
Cumberland Pharmaceuticals Reports Fourth Quarter Revenue Growth Of 16%
- Acquired Vibativ® from Theravance Biopharma - Closed largest product transaction in Company's history - Acquisition funded by $20 million credit line expansion NASHVILLE, Tenn. , Feb. 26, 2019 /PRNewswire/ ...
- ACCESSWIRE•2 months ago
Cumberland Pharmaceuticals Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, ...
- PR Newswire•2 months ago
Cumberland Pharmaceuticals To Announce Fourth Quarter And Annual 2018 Financial Results
NASHVILLE, Tenn. , Feb. 19, 2019 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release fourth quarter and annual 2018 financial results after the market closes ...
- American City Business Journals•3 months ago
The Boss: You can find Cumberland Pharmaceuticals' A.J. Kazimi courtside
As the CEO of Cumberland Pharmaceuticals, A.J. Kazimi runs one of the few drug companies in Nashville’s $46.7 billion health care industry. Under his leadership, Cumberland has partnered with Vanderbilt University, Louisiana State University, University of Mississippi and the University of Tennessee Research Foundation to help develop specialty products to add to the company’s growing portfolio.
- Zacks•3 months ago
Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
Cumberland Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
- American City Business Journals•3 months ago
With $500M in reserve, biotech cuts 49 jobs to focus on maturing drug pipeline
Looking long term, the company says, it cuts 49 jobs as it pushes multiple programs deeper into clinical trials.
- Zacks•3 months ago
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
- Zacks•4 months ago
Flexion Starts Phase III Enrollment on Zilretta for Hip OA
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
- Zacks•4 months ago
Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
Small Drug Stocks Near-Term Outlook Positive, Despite Headwinds
- Simply Wall St.•4 months ago
Is Cumberland Pharmaceuticals Inc.’s (NASDAQ:CPIX) Balance Sheet A Threat To Its Future?
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) is a small-cap stock with a market capitalization of US$96m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...
- Yahoo Finance•5 months ago
U.S. and China set to finalize a trade deal in the next three months
Yahoo Finance's LIVE market coverage and analysis of what you need to watch in the stock market begins each day at 9:00 a.m. ET.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CPIX earnings conference call or presentation 13-Nov-18 9:30pm GMT
Q3 2018 Cumberland Pharmaceuticals Inc Earnings Call
- Zacks•5 months ago
Cumberland Pharmaceuticals (CPIX) Reports Q3 Loss, Misses Revenue Estimates
Cumberland (CPIX) delivered earnings and revenue surprises of 73.68% and -7.28%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•5 months ago
Cumberland: 3Q Earnings Snapshot
On a per-share basis, the Nashville, Tennessee-based company said it had a loss of 11 cents. Losses, adjusted for non-recurring costs and stock option expense, were 5 cents per share. The pharmaceutical ...
- PR Newswire•5 months ago
Cumberland Pharmaceuticals Reports Third Quarter 2018 Financial Results
NASHVILLE, Tenn. , Nov. 13, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company focused on hospital acute care, gastroenterology, and oncology supportive ...
- PR Newswire•5 months ago
Cumberland Pharmaceuticals To Announce Third Quarter 2018 Financial Results
NASHVILLE, Tenn. , Nov. 7, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release third quarter 2018 financial results after the market closes on Tuesday, ...
- American City Business Journals•6 months ago
Nashville pharma company pays $25M for drug brand
VIBATIV is typically used in hospital settings for serious bacterial infections such as MRSA, pneumonia and skin infections.
- PR Newswire•6 months ago
Theravance Biopharma Announces Sale of VIBATIV® (telavancin) to Cumberland Pharmaceuticals
DUBLIN, Nov. 6, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma" or the "Company") today announced the sale of its proprietary antibiotic, VIBATIV® (telavancin), to Cumberland Pharmaceuticals, Inc. (CPIX), a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Under the terms of the agreement, Cumberland will pay Theravance Biopharma a total of $25 million and tiered royalties of up to 20% on future US net product sales. VIBATIV is a once-daily, injectable lipoglycopeptide antibiotic approved in the US for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of S. aureus when alternative treatments are not suitable.
- PR Newswire•6 months ago
Cumberland Pharmaceuticals To Acquire VIBATIV®
NASHVILLE, Tenn., Nov. 6, 2018 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (CPIX) announced today that it has entered into a definitive agreement to acquire VIBATIV® from Theravance Biopharma. Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the delivery of high-quality prescription brands to improve patient care. Theravance Biopharma, Inc. is a diversified pharmaceutical organization with the core purpose of helping improve the lives of patients suffering from serious illness.
- Simply Wall St.•7 months ago
The Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) Ownership Structure Could Be Important
Every investor in Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend Read More...
